A Phase 1, Open-Label, Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VH4527079, Administered Either Intravenously or Subcutaneously to Healthy Adults and Persons With HIV
Latest Information Update: 18 Dec 2024
Price :
$35 *
At a glance
- Drugs VH 4527079 (Primary) ; VH 4527079 (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ViiV Healthcare
- 18 Dec 2024 New trial record